Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,067.22 +2.22 (+0.21%)
Streaming Delayed Price Updated: 3:54 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave ↗
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention. 
Via Benzinga
News headline image
Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants. ↗
For some types of restaurants, the damage is bigger. 
Via Investor's Business Daily
News headline image
Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now? ↗
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response. 
Via Investor's Business Daily
Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategy ↗
Via Chartmill
News headline image
Walmart Got Kicked Out of the $1 Trillion Club. Is the Dividend King Stock a No-Brainer Buy Before the End of May? ↗
Walmart's recent run of outperformance could be coming to an end. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
These players are seeing exciting results in clinical trials. 
Via The Motley Fool
News headline image
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% ↗
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results. 
Via Benzinga
News headline image
Don't Buy Viking Therapeutics Stock Until You Read This ↗
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars. 
Via The Motley Fool
News headline image
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗
The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
The pharma giant is taking steps to expand its portfolio. 
Via The Motley Fool
News headline image
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗
Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Is Viking Therapeutics a Top Takeover Target? ↗
Viking's strong obesity drug data continues fueling acquisition speculation. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 05/18 - 05/22 ↗
Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference ↗
Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials. 
Via Benzinga
News headline image
Pediatrics Medicine Market Size, Industry Report By 2035 ↗
The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
3 Market-Beating Stocks with Exciting Potential
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss ↗
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study. 
Via Benzinga
News headline image
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss ↗
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday. 
Via Investor's Business Daily
News headline image
Could Viking Therapeutics Be the Next Eli Lilly? ↗
Demand for weight loss drugs may fuel growth for more than one player. 
Via The Motley Fool
News headline image
Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗
It's tough to think of an industry with more staying power than healthcare. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
Best Weight Loss Drug Stocks to Buy in 2026 ↗
If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks
Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pha... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗
Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand. 
Via MarketBeat
News headline image
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report ↗
Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage. 
Via Benzinga
Topics Government
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
The company is riding an incredible tailwind. 
Via The Motley Fool
News headline image
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case ↗
Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act. 
Via Benzinga
Topics Fraud Whistleblower
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.